BRIEF-U.S. FDA Approves Second Indication For Skyrizi(Risankizumab-Rzaa) To Treat Adults With Active Psoriatic Arthritis
* U.S. FDA APPROVES SECOND INDICATION FOR SKYRIZI® (RISANKIZUMAB-RZAA) TO TREAT ADULTS WITH ACTIVE PSORIATIC ARTHRITIS
* ABBVIE (ABBV) - SKYRIZI MET PRIMARY ENDPOINT OF ACR20 AT WEEK 24 IN TWO PIVOTAL STUDIES, DEMONSTRATING SIGNIFICANT IMPROVEMENT IN JOINT SYMPTOMS Source text for Eikon: Further company coverage: